Articles Tagged With:
-
Case Management Program Cuts Heart Failure Readmissions in Half
A case management program targeted health improvements among congestive heart failure patients and succeeded in cutting readmission rates to half the national average.
-
Angiotensin II Raises Blood Pressure in Patients with Vasodilatory Shock
Infusion of recombinant angiotensin II improved blood pressure control in patients with vasodilatory shock already receiving conventional vasopressors.
-
Spontaneous Breathing Trials and Occam’s Razor
Different ventilator modes used for a spontaneous breathing trial affected a patient’s work of breathing (WOB) variously and differed regarding WOB measured after extubation. The clinical relevance of these differences is uncertain.
-
Intensive Care Enteral Nutrition in 2017
Enteral nutrition, defined as any method of feeding that uses the gastrointestinal (GI) tract (including oral feeding), usually refers to the delivery of nourishment to the GI tract through a tube. Nutrition is of utmost importance for patients suffering from a critical illness, and EN is a mainstay of nutrition in the ICU. Malnutrition and nutritional risk are common in patients admitted to the ICU. The presence of critical illness causes the body to enter a catabolic state, putting patients at risk of development or worsening of malnutrition. The Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition have published and revised joint guidelines to offer evidence-based recommendations for how best to feed critically ill patients.
-
Study: Trial Results for New Neurological Drugs Often Go Unpublished
Results of clinical trials for “stalled” neurological drugs — those which had at least one completed Phase III trial but failed to receive FDA approval — are heavily underreported, found a new study.
-
AllTrials Seeks Transparency in Big Pharma Studies
The AllTrials campaign, striving to achieve full disclosure of all results in clinical trials, recently conducted an audit of the transparency policies of pharmaceutical companies, finding them open enough on the surface — but beset with devils in the details.
-
Broad Consent Issues raised by SACHRP and Others
With broad consent, patients would have an easy and speedy opportunity to opt out of future research uses of their biospecimens. But if they didn’t opt out — and most people probably would agree to the research use of their specimens — then scientific progress could proceed without the consent roadblock.
-
FDA Lowers the Boom on Stem Cell Clinics
The FDA recently cracked down on two stem cell clinics for questionable research practices, including one clinic that was using smallpox vaccine as part of a treatment protocol.
-
NIH Considers Action on Pay-to-Participate Trials
Recent action by federal authorities against stem cell clinics charged with questionable practices appear to validate concerns raised by bioethicists like Leigh Turner, PhD, who recently warned that some stem cell clinics are charging research subjects exorbitant fees for participation in experimental treatments marketed as clinical trials on ClinicalTrials.gov.
-
IRBs Share Strategies to Prepare for New Common Rule
Some IRBs have been preparing for months for the Jan. 19, 2018, implementation of the new Common Rule. Others have taken a more casual, wait-and-see-if-it’s-delayed approach. IRBs that are preparing for a January rollout have found that preparation is time-consuming and resource-intensive.